21:46:07 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-03-12 Årsstämma 2025
2025-02-05 Bokslutskommuniké 2024
2024-10-22 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-04-23 Kvartalsrapport 2024-Q1
2024-03-13 Ordinarie utdelning OSSR 0.00 DKK
2024-03-13 Årsstämma 2024
2024-03-12 Årsstämma 2024
2024-01-30 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-25 Kvartalsrapport 2023-Q2
2023-04-25 Kvartalsrapport 2023-Q1
2023-03-13 Ordinarie utdelning OSSR 0.00 DKK
2023-03-10 Årsstämma 2023
2023-01-31 Bokslutskommuniké 2022
2022-10-25 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-03-09 Ordinarie utdelning OSSR 0.00 DKK
2022-03-08 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-09 Ordinarie utdelning OSSR 0.00 DKK
2021-03-08 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-07-23 Kvartalsrapport 2020-Q2
2020-04-30 Kvartalsrapport 2020-Q1
2020-03-13 Ordinarie utdelning OSSR 0.15 DKK
2020-03-12 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-30 Kvartalsrapport 2019-Q1
2019-03-08 Ordinarie utdelning OSSR 0.14 DKK
2019-03-07 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-25 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-09 Ordinarie utdelning OSSR 0.13 DKK
2018-03-08 Årsstämma 2018
2018-02-05 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-07-25 Kvartalsrapport 2017-Q2
2017-04-27 Kvartalsrapport 2017-Q1
2017-03-10 Ordinarie utdelning OSSR 0.12 DKK
2016-03-11 Ordinarie utdelning OSSR 0.12 DKK
2016-03-10 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-07-23 Kvartalsrapport 2015-Q2
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-12 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Analytiker möte 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-07-25 Analytiker möte 2014
2014-07-24 Kvartalsrapport 2014-Q2
2014-04-30 Analytiker möte 2014
2014-04-29 Kvartalsrapport 2014-Q1
2014-03-14 Årsstämma 2014
2014-02-05 Bokslutskommuniké 2013
2013-10-24 Analytiker möte 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-07-24 Kvartalsrapport 2013-Q2
2013-04-24 Kvartalsrapport 2013-Q1
2013-03-15 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-11-28 Kapitalmarknadsdag 2012
2012-11-27 Kapitalmarknadsdag 2012
2012-10-24 Analytiker möte 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-07-25 Kvartalsrapport 2012-Q2
2012-04-24 Kvartalsrapport 2012-Q1
2012-03-16 Årsstämma 2012
2012-02-08 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-07-28 Kvartalsrapport 2011-Q2
2011-03-04 Årsstämma 2011

Beskrivning

LandIsland
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Össur hf. är ett isländskt bolag verksamma inom hälsa - och sjukvård. Idag innehas affärsinriktning mot utvecklandet av benproteser, artros samt relaterad skadehantering. Produkterna är anpassade för olika åldrar och förutsättningar beroende på patientens svårighetsgrad. Verksamheten är etablerad globalt med störst marknad inom Europa följt av Nordamerika. Huvudkontoret ligger i Reykjavik.
2019-10-22 08:00:00

Announcement no. 62/2019

Interim report Q3 2019

22 October 2019

Highlights
  • Sales growth of 19% in local currency in Q3 2019 and organic sales growth of 5%. Sales growth of 19% in local currency in 9M 2019 and organic sales growth of 7%.
  • The prosthetics segment grew 6% organic and the B&S segment grew 5% organic. Strong growth is attributed to good sales of high-end solutions and recently launched products.
  • Gross profit margin in Q3 2019 was 64%, same as in the comparable quarter last year. Gross profit margin in 9M 2019 was 64% compared to 63% in the comparable period. The increase is driven by positive impact from changes in product mix, savings from the ongoing efficiency initiatives, and scalability in manufacturing.
  • EBITDA margin before special items was 24% in Q3 2019. EBITDA margin before special items and excluding the impact of IFRS 16 was 21% in Q3 2019 compared to 21% in the comparable quarter. EBITDA margin before special items in 9M 2019 was 22% and excluding the impact of IFRS16 was 19% compared to 18% in 9M 2018. Higher EBITDA margin is a result of changes in product mix, savings from the ongoing efficiency initiatives, scalability, and currency movements.
  • Net profit in Q3 2019 amounted to 9% of sales. Net profit in 9M 2019 amounted to 10% of sales and grew by 12%.
  • Cash generated by operations amounted to 29% of sales in Q3 2019 compared to 22% of sales in the comparable quarter last year. Cash generated by operations amounted to 19% of sales in 9M 2019.
  • Össur acquired 1,167,767 of own shares through the ongoing share buyback program for USD 8 million in Q3 2019. In 9M 2019, Össur acquired 3,259,351 of own shares for USD 19 million.
  • In the beginning of Q4 2019, Össur made two acquisitions with combined full-year sales of about USD 13 million.
  • With strong sales growth in the first nine months of the year, the financial guidance range for organic growth has been narrowed to ~6% (previous 5-6%). The financial guidance for the full year 2019 is therefore ~6% organic sales growth, ~23% EBITDA margin before special items*, 4-5% CAPEX of sales, and an effective tax rate of 23-24%.

Jon Sigurdsson, President & CEO, comments:

"Sales growth in the third quarter of the year was strong with a good contribution from both prosthetics and bracing & supports while bearing in mind a strong comparable quarter last year. Growth drivers in the quarter include our high-end solutions in both prosthetics and bracing & supports products and recently launched products such as the new PROPRIO FOOT® which we launched in the beginning of the year. With strong sales growth in the first nine months of the year, we are narrowing our full year guidance for organic growth to ~6% compared to the previous guidance of 5-6%. The profitability of the company is increasing in the first nine months of the year which can be attributed to favorable changes in product mix, additional savings from the ongoing efficiency initiatives, and scalability."

Q3 2019 conference call details

Össur will host a conference call on 22 October 2019 at 9:00 CET / 7:00 GMT / 3:00 EDT. To participate in the call please dial: Europe: + 45 35 44 55 77, +44 (0) 333 300 0804 or +46 (0) 8 566 426 51, The United States: + 1 631 913 1422, Iceland: +354 800 7437. The PIN CODE to access the call is 19260853#. A webcast can be followed on the Össur website: www.ossur.com/investors.

Further information

David Hreidarsson, Investor Relations, dhreidarsson@ossur.com,+354 515 1380

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors

About Össur

Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations.  Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of Prosthetics and Bracing & Supports.  A recognized "Technology Pioneer," Össur invests significantly in research and product development-its award-winning designs ensuring a consistently strong position in the market.   Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com